Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 43rd Annual J.
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website here. OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large,
Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Frontier Medicines Corporation ("Frontier" or the "Company"), a clinical-stage precision medicine company unlocking to advance transformational therapies, today announced that Chris Varma, Ph.D., Frontier's co-founder,
The J.P. Morgan Healthcare Conference attracts thousands of attendees each year from the provider, insurance, digital health ...
J.P. Morgan Chase, with about 300,000 employees worldwide, is expected to announce the end of hybrid and remote work in the ...
M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...
J.P. Morgan analyst Doug Anmuth said he sees room for Alphabet, Google’s parent, to gain ground on a variety of fronts, ...
J.P. Morgan Asset Management’s Michael Cembalest calls them “Alchemists” — the Trump White House nominees who are looking to ...
Josh Forstater has joined J.P. Morgan Asset Management as managing director, head of Everyday 401 (k), a retirement plan ...
Carvana fell again Friday a day after short-seller Hindenburg Research criticized the used-car retailer in an extensive ...
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced today announced its ...
Marc Turansky is starting in the newly-created role of head of investment advisory programs as of Monday, according to Keith Glenfield, head of investment solutions.
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback